Multiple new drugs for pain management have been recently introduced or approved, and additional agents are currently under investigation.
Administration of abuse-deterrent formulations of immediate-release oxycodone and extended-release morphine leads to slower and lower absorption rates in nondependent recreational drug users compared with standard oxycodone and morphine formulations.
Egalet announced the launch of Arymo ER extended-release tablets for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.
There is a lot of opportunity to improve on what can be offered to patients.
Clinical Pain Advisor Articles
- Chronic Fatigue Syndrome's Cytokine Signature
- Caffeine and Opioid Use Beneficial for Fibromyalgia-Like Chronic Pain
- Vitamin D Deficiency Associated With Neuropathic Pain in Rheumatoid Arthritis
- Pregabalin vs Gabapentin for Neuropathic Pain to Achieve Therapeutic Dose
- An Overview of Using Naloxone and Opioids for Pain Management
- Pilates Effective in Alleviating Chronic Low Back Pain
- Intravenous Lidocaine Safe, Effective for Chronic Pain
- Ozone Safe, Effective for Knee Osteoarthritis Pain
- Neuroinflammation: Treating the Underlying Cause of Chronic, Severe Pain
- Virtual Reality for Pain Management: A Weapon Against the Opioid Epidemic?
- Collaborative Care Superior to Standard Care for Opioid Use Disorder
- Gabapentinoids: Evaluating the Benefits for Chronic Low Back Pain
- Emerging Technology to Help Treat Juvenile Idiopathic Arthritis
- Fired for Falling Asleep During Work Hours: Our Readers Weigh In
- Chemo-Induced Peripheral Neuropathy Risk Reduced With Multivitamin